Institutional members access full text with Ovid®

Share this article on:

Comment on: Rifaximin in the Treatment of Irritable Bowel Syndrome. Is There a High Risk for Development of Antimicrobial Resistance?

Calanni, Fiorella DSc*; Renzulli, Cecilia PhD*; Fogli, Maria V. PhD; Barbanti, Miriam DSc*

Journal of Clinical Gastroenterology: October 2013 - Volume 47 - Issue 9 - p 814
doi: 10.1097/MCG.0b013e3182951b6c
Letters to the Editor

*Preclinical Development

Clinical Development, R&D Alfa Wassermann SpA, Bologna, Italy

F.C., C.R., and M.V.F. report being employees of Alfa Wassermann. M.B. reports that she was an employee of Alfa Wassermann and she is working as preclinical consultant of Alfa Wassermann.

© 2013 by Lippincott Williams & Wilkins